Olgaard K, Hagen C, Madsen S, Hummer L
Acta Endocrinol (Copenh). 1977 Jul;85(3):587-94. doi: 10.1530/acta.0.0850587.
To investigate whether a direct influence exists between the prolactin suppressive effect of alpha-bromoergocriptine (CB 154) and the aldosterone response to a potassium stimulation, the present study was performed in 7 anephric patients and in 7 non-nephrectomized patients, all on regular haemodialysis. The increase in the plasma potassium concentration between dialysis was used as a stimulus to the adrenals, and was correlated to the increase in the plasma aldosterone concentration (PAC). Plasma samples were obtained during a control period and during a corresponding period of treatment with bromocriptine. Despite a significant fall in the prolactin levels during the bromocriptine treatment, no differences in the aldosterone response to the increasing potassium concentration in the two periods were found neither in the anephric nor in the non-nephrectomized patients. It is concluded that depression of prolactin levels by the dopamine agonist (bromocriptine) has no influence on the ability of the adrenals to react with an increase in aldosterone secretion following potassium stimulation in dialysis patients with and without preserved renin-angiotensin system.
为了研究α-溴麦角环肽（CB 154）的催乳素抑制作用与醛固酮对钾刺激的反应之间是否存在直接影响，本研究对7例无肾患者和7例未行肾切除术的患者进行了研究，所有患者均接受定期血液透析。透析期间血浆钾浓度的升高被用作肾上腺的刺激因素，并与血浆醛固酮浓度（PAC）的升高相关。在对照期和溴隐亭治疗的相应期间采集血浆样本。尽管在溴隐亭治疗期间催乳素水平显著下降，但在无肾患者和未行肾切除术的患者中，两个时期醛固酮对钾浓度升高的反应均未发现差异。得出的结论是，多巴胺激动剂（溴隐亭）降低催乳素水平对有和没有保留肾素-血管紧张素系统的透析患者在钾刺激后肾上腺醛固酮分泌增加的反应能力没有影响。
